dc.contributor.author | Tao, Yubing | |
dc.contributor.author | Wang, Fei | |
dc.contributor.author | Shen, Xiaopei | |
dc.contributor.author | Zhu, Guangwu | |
dc.contributor.author | Liu, Rengyun | |
dc.contributor.author | Viola, David | |
dc.contributor.author | Elisei, Rossella | |
dc.contributor.author | Puxeddu, Efisio | |
dc.contributor.author | Fugazzola, Laura | |
dc.contributor.author | Colombo, Carla | |
dc.contributor.author | Jarzab, Barbara | |
dc.contributor.author | Czarniecka, Agnieszka | |
dc.contributor.author | Lam, Alfred K | |
dc.contributor.author | Mian, Caterina | |
dc.contributor.author | et al. | |
dc.date.accessioned | 2021-08-02T01:49:29Z | |
dc.date.available | 2021-08-02T01:49:29Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0021-972X | |
dc.identifier.doi | 10.1210/clinem/dgab286 | |
dc.identifier.uri | http://hdl.handle.net/10072/406478 | |
dc.description.abstract | CONTEXT: How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined. OBJECTIVE: To study whether BRAF V600E affected LNM-associated mortality in PTC. DESIGN, SETTING, PARTICIPANTS: We retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 (IQR 35-58) years and median follow-up time of 58 (IQR 26-107) months. RESULTS: Overall, LNM showed a modest mortality risk in wild-type BRAF patients but a strong one in BRAFV600E patients. In conventional PTC (CPTC), LNM showed no increased mortality risk in wild-type BRAF patients but a robustly increased one in BRAFV600E patients; mortality rates were 2/659 (0.3%) versus 4/321 (1.2%) in non-LNM versus LNM patients (P=0.094) with wild-type BRAF, corresponding to a hazard ratio (HR) (95% CI) of 4.37 (0.80-23.89), which remained insignificant at 3.32 (0.52-21.14) after multivariate adjustment. In BRAFV600E CPTC, morality rates were 7/515 (1.4%) versus 28/363 (7.7%) in non-LNM versus LNM patients (P<0.001), corresponding to HR of 4.90 (2.12-11.29) or, after multivariate adjustment, 5.76 (2.19-15.11). Adjusted mortality HR of coexisting LNM and BRAFV600E versus absence of both was 27.39 (5.15-145.80), with Kaplan-Meier analyses showing a similar synergism. CONCLUSIONS: LNM-associated mortality risk is sharply differentiated by the BRAF status in PTC; in CPTC, LNM showed no increased mortality risk with wild-type BRAF but a robust one with BRAF mutation. These results have strong clinical relevance. | |
dc.description.peerreviewed | Yes | |
dc.language | eng | |
dc.publisher | The Endocrine Society | |
dc.relation.ispartofjournal | The Journal of Clinical Endocrinology & Metabolism | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.keywords | BRAF mutation | |
dc.subject.keywords | lymph node metastasis | |
dc.subject.keywords | mortality | |
dc.subject.keywords | prognostic molecular marker | |
dc.subject.keywords | risk stratification | |
dc.title | BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Tao, Y; Wang, F; Shen, X; Zhu, G; Liu, R; Viola, D; Elisei, R; Puxeddu, E; Fugazzola, L; Colombo, C; Jarzab, B; Czarniecka, A; Lam, AK; et al., BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, 2021 | |
dc.date.updated | 2021-07-27T22:24:27Z | |
dc.description.version | Accepted Manuscript (AM) | |
gro.description.notepublic | This publication has been entered as an advanced online version in Griffith Research Online. | |
gro.rights.copyright | © 2021 Oxford University Press. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in the Journal of Clinical Endocrinology and Metabolism following peer review. The definitive publisher-authenticated version BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer, Journal of Clinical Endocrinology and Metabolism, 2021 is available online at: https://doi.org/10.1210/clinem/dgab286. | |
gro.hasfulltext | Full Text | |
gro.griffith.author | Lam, Alfred K. | |